do glp 1 drugs lower cholesterol can help with GLP-1 medications are changing obesity and metabolic care — but Why are GLP-1 agonists being

Introduction:- Diabetes is a chronic condition that affects millions of people worldwide

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

Compared with LIXI, LIR is more effective in improving blood glucose and reducing weight, and both treatments are well tolerated (75, 77, 78)

[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Ratner RE, Rosenstock J, Boka G

The use of the unimolecular triple agonist GIP-Oxm is also significantly potent in improving bone strength and restoring trabecular bone mass [865]

[DOI] [PubMed] [Google Scholar] 685.Clemmensen C., Finan B., Fischer K., Tom R.Z., Legutko B., Sehrer L